Cost-Effectiveness Analysis of
68Ga-DOTA-TATE PET/CT
cost-effectiveness
neuroendocrine tumors
nuclear imaging
Journal
Diagnostics (Basel, Switzerland)
ISSN: 2075-4418
Titre abrégé: Diagnostics (Basel)
Pays: Switzerland
ID NLM: 101658402
Informations de publication
Date de publication:
18 Feb 2021
18 Feb 2021
Historique:
received:
29
01
2021
revised:
11
02
2021
accepted:
15
02
2021
entrez:
6
3
2021
pubmed:
7
3
2021
medline:
7
3
2021
Statut:
epublish
Résumé
Neuroendocrine tumors (NETs) are relatively rare neoplasms arising from the hormone-producing neuroendocrine system that can occur in various organs such as pancreas, small bowel, stomach and lung. As the majority of these tumors express somatostatin receptors (SSR) on their cell membrane, utilization of SSR analogs in nuclear medicine is a promising, but relatively costly approach for detection and localization. The aim of this study was to analyze the cost-effectiveness of
Identifiants
pubmed: 33670457
pii: diagnostics11020334
doi: 10.3390/diagnostics11020334
pmc: PMC7922846
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
Medicine (Baltimore). 2019 Aug;98(33):e16843
pubmed: 31415409
Mol Imaging Biol. 2011 Jun;13(3):583-593
pubmed: 20652423
Endocr Relat Cancer. 2013 Mar 22;20(2):187-96
pubmed: 23319495
Value Health. 2016 Dec;19(8):929-935
pubmed: 27987642
Nucl Med Mol Imaging. 2015 Dec;49(4):284-90
pubmed: 26550047
J Med Imaging Radiat Oncol. 2018 Feb;62(1):57-63
pubmed: 28714296
Lancet Oncol. 2008 Jan;9(1):61-72
pubmed: 18177818
Ann Nucl Med. 2018 Aug;32(7):446-452
pubmed: 29926342
J Clin Oncol. 2004 Jul 1;22(13):2724-9
pubmed: 15226340
Eur J Nucl Med Mol Imaging. 2016 Jul;43(7):1258-66
pubmed: 26819103
J Clin Oncol. 2008 Jun 20;26(18):3063-72
pubmed: 18565894
Am J Clin Oncol. 2019 Aug;42(8):668-674
pubmed: 31343423
Eur J Health Econ. 2019 Mar;20(2):175-180
pubmed: 30187251
Curr Opin Endocrinol Diabetes Obes. 2018 Feb;25(1):22-35
pubmed: 29120923
EJNMMI Phys. 2015 Dec;2(1):3
pubmed: 26501805
Surgery. 2015 Aug;158(2):339-48
pubmed: 25999251
Eur Urol Focus. 2020 Sep 15;6(5):967-974
pubmed: 30826284
Mol Imaging Biol. 2003 Jan-Feb;5(1):42-8
pubmed: 14499161
Eur J Nucl Med Mol Imaging. 2012 Jan;39(1):72-82
pubmed: 21927931
Cancer Manag Res. 2018 Nov 13;10:5629-5638
pubmed: 30519109
JAMA Oncol. 2017 Oct 1;3(10):1335-1342
pubmed: 28448665
Endocr Relat Cancer. 2020 Jun;27(6):R211-R218
pubmed: 32276263
Pancreas. 2012 Apr;41(3):461-6
pubmed: 22422138
Neuroendocrinology. 2020 Jun 24;:
pubmed: 32580192
JAMA. 2016 Sep 13;316(10):1093-103
pubmed: 27623463
Eur J Cancer. 2013 May;49(8):1975-83
pubmed: 23352435
J Med Econ. 2012;15 Suppl 1:55-64
pubmed: 22881362
Health Technol Assess. 2008 Apr;12(7):iii, ix-x, 1-175
pubmed: 18373906
Support Care Cancer. 2016 Sep;24(9):3695-703
pubmed: 27029477
Curr Oncol. 2018 Feb;25(1):32-40
pubmed: 29507481
N Engl J Med. 2017 Jan 12;376(2):125-135
pubmed: 28076709
J Nucl Med. 2017 Mar;58(3):451-457
pubmed: 27660147
BMJ. 2013 Mar 25;346:f1049
pubmed: 23529982
Ther Adv Endocrinol Metab. 2019 Feb 18;10:2042018819828217
pubmed: 30815246
Clin Radiol. 2008 Mar;63(3):241-51
pubmed: 18275863
Surg Oncol Clin N Am. 2020 Apr;29(2):209-221
pubmed: 32151356
Neuroendocrinology. 2017 Mar 30;105(3):212-244
pubmed: 28355596
Medicine (Baltimore). 2020 Feb;99(7):e19162
pubmed: 32049844
Am J Nucl Med Mol Imaging. 2012;2(2):221-31
pubmed: 23133813
Trends Pharmacol Sci. 1995 Mar;16(3):86-8
pubmed: 7792934
Med J Aust. 2020 Jul;213(2):72-73
pubmed: 32598481
Asia Ocean J Nucl Med Biol. 2019 Spring;7(2):129-140
pubmed: 31380452
Neuroendocrinology. 2020;110(6):444-476
pubmed: 31557758